© MediPaper 2016 ASCO 2016 Atezolizumab Data MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after.

Slides:



Advertisements
Similar presentations
James R. Rigas Comprehensive Thoracic Oncology Program
Advertisements

Metastatic Gastric Cancer
Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab:
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.
First-Line TKI Use in EGFR Mutation-Positive NSCLC
Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.
O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
Adam Heathfield, PhD Senior Director, Worldwide Policy, Pfizer Inc. September 25, 2013 Personalised Medicine – an industry perspective.
Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic.
Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
May 29 - June 2, 2015 Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer CCO Independent Conference.
ASCO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR
© MediPaper 2016 ASCO 2016 Palbociclib (Ibrance™) Data MediPaper Study / AbstractPhIndicationLineNN BiomarkerMethodologyArms1 o EPORRCBRDCRmPF S (Mo) PFS.
© MediPaper 2016 ASCO 2016 Ipilimumab Data - Melanoma MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmDR (Mo) mPFS (Mo) PFS ratemOS (Mo) OS rate.
Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )
ASCO 2016 Pembrolizumab Data - Melanoma
POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.
May 29 – June 2, 2015 Lung Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO is an independent medical education company.
May 29 - June 2, 2015 KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1- Positive Extensive-Stage SCLC CCO Independent Conference.
CCO Independent Conference Coverage
ESMO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR
Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
CCO Independent Conference Highlights
KEYNOTE-045: Updated Survival Analysis of Phase III Trial of Pembrolizumab vs Paclitaxel, Docetaxel, or Vinflunine in Pts With Advanced Urothelial Carcinoma.
ESMO 2016 Durvalumab Data Study / Abstract Ph Indication Line N Arms
Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology
KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer
CCO Independent Conference Highlights
CCO Independent Conference Coverage
CCO Independent Conference Highlights
Alessandra Gennari, MD PhD
N Engl J Med; Volume 373(17): ; October 22, 2015
KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC CCO Independent Conference Highlights* of.
Azienda Ospedaliero Universitaria Policlinico Modena
CCO Independent Conference Coverage
IMvigor 210 (Cohort 1): First-line Atezolizumab in Cisplatin-Ineligible Metastatic Urothelial Carcinoma CCO Independent Conference Coverage* of the 2016.
ECHO-204: Preliminary Results of Phase I/II Trial of Epacadostat + Nivolumab in Advanced Solid Tumors CCO Independent Conference Highlights* of the 2017.
CCO Independent Conference Coverage
ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
CCO Independent Conference Highlights
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
CCO Independent Conference Coverage
Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CCO Independent Conference Coverage
Abraxane-Pembro nei carcinomi uroteliali avanzati
CCO Independent Conference Coverage
Intervista a Lucio Crinò
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
Lancet Oncol 2016;17(11): Updated Results from KEYNOTE-021 Cohort G: A Randomized, Phase 2 Study of Pemetrexed and Carboplatin (PC) with or without.
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
Axel Grothey Professor of Oncology Mayo Clinic Rochester
Rossi A et al. Proc ASCO 2011;Abstract 8008.
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Domenica 03 giugno Highlight a cura di Filippo de Marinis
Progression-Free Survival Times Overall Survival Times
Lunedì 04 giugno Highlight a cura di Filippo de Marinis
R Hermann6, P Sportelli7, L Gardner7 and J Bendell8
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Presentation transcript:

© MediPaper 2016 ASCO 2016 Atezolizumab Data MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after Sunday June 5, 11:00 AM CTZ POPLARPOPLAR 9028IINSCLC2 nd / 3 rd TC3 / IC3 23 TC3 / IC3 50 TC2/3 / IC 2/3 55 TC2/3 / IC 2/3 93 TC1/2/3 / IC1/2/3 102 TC1/2/3 / IC1/2/3 51 TC0/ IC0 41 TC0/ IC0 49 Squamous 48 Squamous 95 Non-Squamous 95 Non-Squamous Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 mg IV q3w Doc q3w atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w OS NR POPLARPOPLAR 9032IINSCLC2 nd / 3 rd 144 imRECIST 144 RECIST 57 Atezo after PD 30 Other after PD Atezo 1200 mg IV q3w Atezo 1200 mg IV q3w Atezo 1200 q3w —> PD —> Atezo dose ND Atezo 1200 q3w —> PD —> Other Tx OS17% 15% 14% IMvigor210IImUC ≧ 2 nd 100 IC2/3 imRECIST 207 IC1/2/3 imRECIST 310 IC0/1/2/3 imRECIST 100 IC2/3 RECIST 207 IC1/2/3 RECIST 310 IC0/1/2/3 RECIST Plat CTx —> PD —> R —> Atezo 1200 q3w 29% 23% 19% 26% 18% 15% (1- Yr) 40 (1- Yr) 37 (1- Yr) Abstract 35021bCRC ≧ 1 st 23 (22 KRASmu)Cobi + Atezo 800 q2wMTD (NR)17% Abstract 10091bmTNBC1 st 2 nd ≧ 3 rd ≧ 1 st (All) Atezo 800 q2w + Pac Safety & tolerability (NR) 67%, 89% 35%, 75% 29%, 43% 42%, 71% (Conf., TBC) Treatments: Atezo 800 = Atezolizumab 800 mg IV; Atezo 1200 = Atezolizumab 1200 mg IV; Cobi = cobimetinib mg daily 3wk on, 1 wk off; Doc = docetaxel 75 mg/m 2 ; IV; Pac = Nab-paclitaxel 125 mg/m 2 on d1,8,15 of 28 day cycles;Tx = Treatment. Abbreviations: 1 o EP = Primary Endpoint; BRAFmu = BRAF mutation; C2 = Cohort 2; Conf. = Confirmed; CRC = Colorectal Cancer; IC3/2/1/0 = high/medium/low/very low PDL1 expression on tumor-infiltrating immune cells; mOS = median Overall Survival; Mo = Months; mPFS = median Progression Free Survival; mTNBC = metastatic Triple Negative Breast Cancer; mUC = metastatic urothelial cancer; NR = Not Reported; NSCLC = non-small cell lung cancer; ORR = Overall Response Rate; OS; Overall Survival; PFS: Progression Free Survival; Ph = Phase; qXwk = every X weeks; R = Registration; TBC = To be confirmed; TC3/2/1/0 = high/medium/low/very low PD-L1 expression on tumor cells; Wk = Weeks; Yr = Year.

© MediPaper 2016 ASCO 2016 Atezolizumab Data Courtesy of MediPaper Medical Writers - Medi-Paper.comMedi-Paper.com Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after Sunday June 5, 11:00 AM CTZ POPLARPOPLAR 9028IINSCLC2 nd / 3 rd TC3 / IC3 23 TC3 / IC3 50 TC2/3 / IC 2/3 55 TC2/3 / IC 2/3 93 TC1/2/3 / IC1/2/3 102 TC1/2/3 / IC1/2/3 51 TC0/ IC0 41 TC0/ IC0 49 Squamous 48 Squamous 95 Non-Squamous 95 Non-Squamous Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 mg IV q3w Doc q3w atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w OS NR POPLARPOPLAR 9032IINSCLC2 nd / 3 rd 144 imRECIST 144 RECIST 57 Atezo after PD 30 Other after PD Atezo 1200 mg IV q3w Atezo 1200 mg IV q3w Atezo 1200 q3w —> PD —> Atezo dose ND Atezo 1200 q3w —> PD —> Other Tx OS17% 15% 14% IMvigor210IImUC ≧ 2 nd 100 IC2/3 imRECIST 207 IC1/2/3 imRECIST 310 IC0/1/2/3 imRECIST 100 IC2/3 RECIST 207 IC1/2/3 RECIST 310 IC0/1/2/3 RECIST Plat CTx —> PD —> R —> Atezo 1200 q3w 29% 23% 19% 26% 18% 15% (1- Yr) 40 (1- Yr) 37 (1- Yr) Abstract 35021bCRC ≧ 1 st 23 (22 KRASmu)Cobi + Atezo 800 q2wMTD (NR)17% Abstract 10091bmTNBC1 st 2 nd ≧ 3 rd ≧ 1 st (All) Atezo 800 q2w + Pac Safety & tolerability (NR) 67%, 89% 35%, 75% 29%, 43% 42%, 71% (Conf., TBC) Treatments: Atezo 800 = Atezolizumab 800 mg IV; Atezo 1200 = Atezolizumab 1200 mg IV; Cobi = cobimetinib mg daily 3wk on, 1 wk off; Doc = docetaxel 75 mg/m 2 ; IV; Pac = Nab-paclitaxel 125 mg/m 2 on d1,8,15 of 28 day cycles;Tx = Treatment. Abbreviations: 1 o EP = Primary Endpoint; BRAFmu = BRAF mutation; C2 = Cohort 2; Conf. = Confirmed; CRC = Colorectal Cancer; IC3/2/1/0 = high/medium/low/very low PDL1 expression on tumor-infiltrating immune cells; mOS = median Overall Survival; Mo = Months; mPFS = median Progression Free Survival; mTNBC = metastatic Triple Negative Breast Cancer; mUC = metastatic urothelial cancer; NR = Not Reported; NSCLC = non-small cell lung cancer; ORR = Overall Response Rate; OS; Overall Survival; PFS: Progression Free Survival; Ph = Phase; qXwk = every X weeks; R = Registration; TBC = To be confirmed; TC3/2/1/0 = high/medium/low/very low PD-L1 expression on tumor cells; Wk = Weeks; Yr = Year.